The main differences and clinical application comparison between cabozantinib and lenvatinib

Cabozantinib (Cabozantinib) and Lenvatinib (Lenvatinib) are both targeted therapy drugs that have been widely used in the field of tumor treatment in recent years, especially in the treatment of various malignant tumors such as liver cancer and renal cancer. Both have shown good efficacy. Both drugs are multi-target tyrosine kinase inhibitors (TKIs), but there are certain differences in their mechanisms of action, indications, efficacy, and drug resistance. Understanding these differences has important implications for patient treatment options.

Cabotinib is a multi-target small molecule drug that mainly achieves anti-tumor effects by inhibitingVEGFR (vascular endothelial growth factor receptor), MET (hepatocyte growth factor receptor), AXL and other signaling pathways. It can effectively inhibit tumor angiogenesis, inhibit tumor cell proliferation and metastasis, thereby delaying tumor progression. Cabozantinib has shown remarkable efficacy in the treatment of liver cancer, kidney cancer, thyroid cancer, etc., especially in the treatment of advanced or recurrent liver cancer, it has become an important treatment option for patients.

Similar to cabozantinib, lenvatinib is also a multi-target tyrosine kinase inhibitor. It mainly targets VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, PDGFRα (platelet-derived growth factor receptor α) and KIT receptors to inhibit tumor angiogenesis and cell proliferation. Lenvatinib has not only achieved significant results in the treatment of liver cancer, but has also shown good clinical efficacy in various tumors such as renal cancer and thyroid cancer. Compared with cabozantinib, lenvatinib has a stronger effect on the inhibition of VEGFR2, FGFR and PDGFR, and therefore has unique advantages in tumor angiogenesis.

Although the targets of these two drugs are different, their application effects in treatment are very significant, especially in the treatment of advanced liver cancer, both of which have made important breakthroughs. Cabozantinib has been shown in multiple clinical studies to effectively prolong overall survival (OS) and progression-free survival (PFS) in patients with liver cancer. For example, in a clinical trial involving liver cancer, cabozantinib combined with sorafenib significantly improved patient survival. Lenvatinib has shown good efficacy when used in combination with other drugs, especially when used as a single drug, and its therapeutic effect on advanced liver cancer has also been clinically verified.

In terms of side effects, both cabozantinib and lenvatinib are tyrosine kinase inhibitors, so their side effects are somewhat similar. Common side effects include high blood pressure, diarrhea, loss of appetite, fatigue, abnormal liver function, etc. Especially for hypertension and abnormal liver function, patients need to be monitored regularly during treatment. Lenvatinib has also shown similar side effects in clinical use, especially hypertension and liver function problems. When patients use these drugs, doctors usually adjust the dosage based on the symptoms of side effects to ensure the safety and effectiveness of the treatment.

Reference materials:https://everyone.org/explore/compare?id1=45&id2=70